Harvard Bioscience, Inc.HBIONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -13.38% | -12.78% | -11.17% | -11.46% | -6.28% |
| Gross Profit Growth | -13.32% | -6.21% | -17.52% | -21.54% | -5.83% |
| EBITDA Growth | -186.71% | +118.78% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -96.10% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.17% | +1.94% | +1.60% | +1.88% | +2.16% |
| Weighted Average Shares Diluted Growth | +2.17% | +1.94% | +1.60% | +1.88% | +2.16% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -119.31% | -59.91% | +112.83% | +0.00% | +0.00% |
| Free Cash Flow Growth | -149.32% | -61.17% | +262.08% | +0.00% | +0.00% |
| Receivables Growth | -14.36% | -7.66% | -11.95% | -4.40% | -5.63% |
| Inventory Growth | +0.67% | -5.95% | -5.47% | -11.44% | -16.88% |
| Asset Growth | -6.08% | -7.81% | -40.07% | -37.87% | -40.57% |
| Book Value per Share Growth | -13.93% | -14.97% | -78.78% | -77.04% | -78.92% |
| Debt Growth | +0.89% | +4.03% | +7.84% | +4.49% | -6.36% |
| R&D Expense Growth | -6.99% | -26.10% | -19.55% | -16.64% | -16.95% |
| SG&A Expenses Growth | -8.49% | -11.37% | -14.42% | -20.58% | -16.76% |